CClinicalTrials.gg
CompletedNCT07431905Updated Feb 25, 2026

Effect of Erector Spinae Plane Block on Postoperative Analgesia and Stress Response in Laparoscopic Sleeve Gastrectomy

An interventional study of Erector Spinae Plane Block and Control in Bariatric Sleeve Gastrectomy, Erector Spina Plan Block and Cortisol, sponsored by Harran University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Harran University · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Feb 2023, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Effective postoperative analgesia is an important component of enhanced recovery after bariatric surgery. The erector spinae plane block (ESPB) is a regional anesthesia technique that has been increasingly used in abdominal and thoracic surgeries; however, its effects on postoperative analgesic requirements, pain scores, patient and surgeon satisfaction, hemodynamic parameters, and perioperative stress response in obese patients undergoing sleeve gastrectomy require further evaluation.

This study is designed as a prospective, randomized, single-blind clinical trial. After obtaining ethics committee approval (Şanlıurfa Harran University Hospital, date: 23.01.2023; decision no: HRÜ/23.02.09) and written/verbal informed consent, 60 patients aged 18-65 years, with a body mass index (BMI) >30 and classified as ASA II-III, scheduled for elective sleeve gastrectomy will be included. Patients will be randomized into two groups: a group receiving bilateral ESPB (Group E, n=30) and a control group without ESPB (Group C, n=30).

Demographic characteristics, ASA classification, comorbidities, and duration of surgery will be recorded. Preoperative venous blood samples will be collected for hemogram (white blood cell count, lymphocyte count, neutrophil count) and biochemical analyses (C-reactive protein, cortisol, and glucose). Standard intraoperative monitoring (electrocardiography, peripheral oxygen saturation, and noninvasive blood pressure) will be applied, and heart rate (HR) and mean arterial pressure (MAP) will be recorded intraoperatively.

Postoperatively, HR and MAP, Numerical Rating Scale (NRS) pain scores at 0, 2, 4, 8, and 24 hours, opioid consumption, patient and surgeon satisfaction scores (Likert scale), postoperative hemogram and biochemical parameters, and any side effects or complications will be documented. All patients will receive dexketoprofen as baseline analgesia, and tramadol hydrochloride will be administered as rescue analgesic when required.

The primary objective of the study is to compare postoperative pain scores and analgesic requirements between patients receiving bilateral ESPB and those not receiving ESPB. Secondary objectives include the assessment of hemodynamic parameters, patient and surgeon satisfaction, and perioperative hematologic, biochemical, and stress-related parameters.

02

Conditions studied

  • Bariatric Sleeve Gastrectomy
  • Erector Spina Plan Block
  • Cortisol
  • Numerical Rating Scale
  • Opioid Analgesia
03

In context

Lead sponsor

Harran University is the lead sponsor of 60 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age between 18 and 65 years
  • Body mass index (BMI) > 30 kg/m²
  • ASA physical status II-III
  • Scheduled for elective laparoscopic sleeve gastrectomy under general anesthesia
  • Ability to provide written and verbal informed consent

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years or > 65 years
  • ASA physical status I, IV, or V
  • Body mass index (BMI) \< 30 kg/m²
  • Contraindications to erector spinae plane block (e.g., infection at injection site, coagulopathy, allergy to local anesthetics)
  • Renal or hepatic insufficiency
  • Refusal to participate or inability to provide informed consent
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Group ESPB

    Procedure: Erector Spinae Plane Block

  • Placebo comparator
    Group Control

    Procedure: Control

Interventions

  • ProcedureErector Spinae Plane Block

    Patients in the intervention group received a preoperative bilateral ultrasound-guided erector spinae plane block (ESPB) in addition to standardized general anesthesia and multimodal analgesia. The block was performed 30 minutes before surgery in the preoperative area by an experienced anesthesiologist under aseptic conditions. With the patient in the prone position, a linear ultrasound probe was placed at the T7-T8 vertebral level to identify the transverse process and erector spinae muscle. Using an in-plane technique, a 22-gauge, 100-mm needle was advanced to the transverse process, and 20 mL of a local anesthetic mixture (lidocaine 2%, bupivacaine 0.25%, and saline) was injected into the fascial plane deep to the erector spinae muscle on each side. Dermatomal sensory assessment was performed before transfer to the operating room. All patients subsequently underwent identical general anesthesia protocols. The control group did not receive any regional block and was managed with the

  • ProcedureControl

    Patients allocated to the control group received standardized general anesthesia and postoperative multimodal analgesia without any regional anesthesia technique. No erector spinae plane block or other peripheral nerve block was performed. General anesthesia induction and maintenance protocols were identical to those used in the intervention group, ensuring comparable intraoperative management. At the end of surgery, all patients received intravenous tramadol as part of the standardized analgesic regimen. Postoperatively, scheduled non-opioid analgesia was administered to all patients. Intravenous tramadol was provided as rescue analgesia when Numerical Rating Scale (NRS) pain scores were ≥4 or upon patient request. Perioperative monitoring, postoperative assessments, and data collection procedures were identical between groups.

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale (NRS)

    The Numerical Rating Scale is an 11-point scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity.

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Body Weight (kilograms)

    Body weight measured in kilograms (kg) using a calibrated hospital scale. Higher values indicate greater body weight.

    Time frame: At baseline (preoperatively)

  2. Height (centimeters)

    Height measured in centimeters (cm) using a standard stadiometer. Higher values indicate greater height.

    Time frame: At baseline (preoperatively)

  3. Body Mass Index (BMI, kg/m²)

    Calculated as weight (kg) divided by height squared (m²).

    Time frame: At baseline (preoperatively)

  4. Postoperative Rescue Opioid Consumption (Intravenous Tramadol, mg)

    Time frame: During the first 24 hours postoperatively

  5. Perioperative Heart Rate (beats per minute)

    Time frame: Intraoperatively and during the first 24 hours postoperatively

  6. Mean Arterial Pressure (mmHg)

    Time frame: Intraoperatively and during the first 24 hours postoperatively

  7. Patient Satisfaction Assessed by a 5-Point Likert Scale at 24 Hours

    5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction.

    Time frame: 24 hours postoperatively

  8. Serum Cortisol Level (mg/dL)

    Time frame: From preoperative baseline to 24 hours postoperatively

  9. Serum C-Reactive Protein (CRP) Level (mg/L)

    Time frame: From preoperative baseline to 24 hours postoperatively

  10. Blood Glucose Level (mg/dL)

    Time frame: From preoperative baseline to 24 hours postoperatively

  11. White Blood Cell Count (×10³/mm³)

    Time frame: From preoperative baseline to 24 hours postoperatively

  12. Lymphocyte Percentage (%)

    Time frame: From preoperative baseline to 24 hours postoperatively

  13. Absolute Lymphocyte Count (×10³/mm³)

    Time frame: From preoperative baseline to 24 hours postoperatively

  14. Neutrophil Percentage (%)

    Time frame: From preoperative baseline to 24 hours postoperatively

  15. Absolute Neutrophil Count (×10³/mm³)

    Time frame: From preoperative baseline to 24 hours postoperatively

07

Study locations

1 site
  • Harran University
    Adana, 01360, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431905
Lead sponsor
Harran University
Responsible party
Kutay Baris FILAZI (Medical Doctor, Harran University) — Principal investigator
First posted
Feb 25, 2026
Start date
Feb 5, 2023
Primary completion
Feb 10, 2024
Completion
Mar 17, 2024
Last update
Feb 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion